Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atypical Antipsychotics Clear all
Completed Phase 2 Interventional Results available

Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

NCT00692185
View directory record Official record
Conditions
Eating Disorders
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Caplyta in Borderline Personality Disorder

NCT05356013
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Caplyta, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 3 Interventional

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
69
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Not applicable Interventional Results available

Pharmacological Management of Delirium

NCT00842608
View directory record Official record
Conditions
Delirium, Cognitive Impairment
Interventions
Reduced exposure to anticholinergics, Reduced exposure to benzodiazepines, Haloperidol, Usual care
Behavioral · Procedure · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational

Cross-Sectional Iloperidone IVGTT

NCT01686815
View directory record Official record
Conditions
Schizophrenia, Serious Mental Illness, Metabolic Syndrome, Insulin Resistance, Glucose Metabolism
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 22, 2026, 2:13 AM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering

NCT01684657
View directory record Official record
Conditions
Stuttering
Interventions
Asenapine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Results available

Allopurinol Add-on Treatment for Refractory Mania

NCT00643123
View directory record Official record
Conditions
Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 3 Interventional

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCT00347425
View directory record Official record
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Results available

Brexpiprazole for Bipolar Depression

NCT03427892
View directory record Official record
Conditions
Bipolar Depression
Interventions
Brexpiprazole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Early Phase 1 Interventional

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

NCT04280965
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Quetiapine Fumarate, Standard of care meducations
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 2:13 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Children With ADHD Who do Not Fully Respond to Stimulants

NCT00279409
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
aripiprazole, Sugar pill
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa

NCT00685334
View directory record Official record
Conditions
Eating Disorders
Interventions
Olanzapine, Aripiprazole
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

NCT00073164
View directory record Official record
Conditions
Schizophrenia
Interventions
Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
35
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 3 Interventional

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00107939
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Licarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
22
States / cities
Little Rock, Arkansas • Orange, California • Pico Rivera, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

NCT01552772
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Not applicable Interventional

Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia

NCT00552500
View directory record Official record
Conditions
Insulin Resistance, Body Composition
Interventions
Depakote (valproate)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 3 Interventional

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

NCT02731612
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lurasidone, Placebo
Drug · Other
Lead sponsor
Lakshmi N Yatham
Other
Eligibility
19 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

NCT00001656
View directory record Official record
Conditions
Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
Interventions
Olanzapine, Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational

Relative Effectiveness of Schizophrenia Therapy Study

NCT01245348
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
SULT4A1-1 genetic test
Genetic
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 22, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain

NCT02281162
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
Interventions
Blood Draw
Other
Lead sponsor
Creighton University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 22, 2026, 2:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

NCT00699946
View directory record Official record
Conditions
Delirium
Interventions
olanzapine, placebo
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
65 Years and older
Enrollment
495 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 22, 2026, 2:13 AM EDT
Recruiting Phase 3 Interventional

Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)

NCT06333990
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Quetiapine Fumarate, TAU
Drug
Lead sponsor
Foundation for Advancing Veterans' Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 22, 2026, 2:13 AM EDT